why choose us

First received: November 29, 2022

Clinical Trial: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Diffuse Large B Cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: Efficacy and Safety of Epcoritamab Monotherapy and in Combination With Lenalidomide as First-line Therapy for Anthracycline-ineligible Diffuse Large B-Cell Lymphoma Patients, an Open-label, Randomized

Brief Summary: The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy.Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies.All patients will receive active treatment.There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.

Read more